ID: ALA178711

Max Phase: Preclinical

Molecular Formula: C20H17N3S2

Molecular Weight: 363.51

Molecule Type: Small molecule

Representations

Canonical SMILES:  c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1

Standard InChI:  InChI=1S/C20H17N3S2/c1-3-15(11-21-9-1)19-7-5-17(24-19)13-23-14-18-6-8-20(25-18)16-4-2-10-22-12-16/h1-12,23H,13-14H2

Standard InChI Key:  CKCZUAVVHJHNJY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 363.51

Molecular Weight (Monoisotopic): 363.0864

AlogP: 5.22

#Rotatable Bonds: 6

Polar Surface Area: 37.81

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.65

CX LogP: 3.93

CX LogD: 2.67

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.51

Np Likeness Score: -1.07

References

1. Denton TT, Zhang X, Cashman JR..  (2005)  5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.,  48  (1): [PMID:15634016] [10.1021/jm049696n]

2.  (2013)  Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data